Chairmans Address to Shareholders
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Lead drug candidate receives positive opinion from EMA
- Appendix 4E & Annual Report 2019
- Successful Completion of Phase 1 Clinical Trial
- Alterity presents initial Phase 1 clinical trial data at AAN
- Prana receives A$3.3 million R&D Tax Incentive Refund
Later from Alterity Therapeutics
- AGM Presentation 2019
- European Orphan Designation granted for PBT434 for MSA
- Alterity receives a $4.8 million R&D Tax Incentive Refund
- Appendix 4C - quarterly
- NASDAQ Non-Compliance Notice Received
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics